(Reuters) – Pfizer Inc’s diabetes drug resulted in weight loss similar to that of Novo Nordisk’s Ozempic in a mid-stage study testing it in patients with type 2 diabates, according to a study published in JAMA network.
Shares of Pfizer rose about 4% following the news.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)
